metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - all population
versus placebo plus SoC
	sintillimab plus SoC vs. placebo plus SoC	1	0.61 [0.40; 0.93], 1 RCT, I2=0% unassessable degree of certainty	0.48 [0.36; 0.64], 1 RCT, I2=0% conclusive unassessable degree of certainty	-
versus Standard of Care (SoC)
	cemiplimab vs. Standard of Care (SoC)	1	0.68 [0.53; 0.87], 1 RCT, I2=0% conclusive unassessable degree of certainty	0.59 [0.49; 0.72], 1 RCT, I2=0% conclusive unassessable degree of certainty	-
	durvalumab alone vs. Standard of Care (SoC)	1	0.96 [0.81; 1.13], 1 RCT, I2=0% inconclusive result	-	-
	durvalumab plus tremelimumab vs. Standard of Care (SoC)	1	0.94 [0.80; 1.11], 1 RCT, I2=0% inconclusive result	-	-
	nivolumab plus ipilimumab plus SoC vs. Standard of Care (SoC)	1	0.69 [0.55; 0.87], 1 RCT, I2=0% conclusive unassessable degree of certainty	0.70 [0.57; 0.86], 1 RCT, I2=0% conclusive unassessable degree of certainty	-